Sirtex Medical Reports 100% Tumor Control in DOORwaY90
Woburn, Massachusetts | April 13, 2026 Sirtex Medical has announced groundbreaking results from its DOORwaY90 clinical study, demonstrating 100%...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Woburn, Massachusetts | April 13, 2026 Sirtex Medical has announced groundbreaking results from its DOORwaY90 clinical study, demonstrating 100%...
Queensbury, New York, USA, April 6, 2026 ESMO Guideline Inclusion Validates CHEMOSAT Therapy In a major milestone for interventional...
